Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B randomized dose-ranging study of PD 0348292 vs enoxaparin for prevention of venous thromboembolic events after total knee replacement
2005-005179-14Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Eribaxaban in venous thromboembolism (VTE) (2 arms), sponsored by Pfizer. Primary endpoint: Total venous thromboembolic events. Started Jan 2006; status: completed.
02
Drugs
Eribaxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2005-005179-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005179-14.